sarcoidosi
multisystem
granulomat
diseas
whose
aetiolog
obscur
controversi
nevertheless
condit
rel
common
significantli
higher
ageadjust
annual
incid
africanamerican
versu
caucasianamerican
estim
one
million
peopl
usa
diseas
base
current
us
popul
approxim
new
case
sarcoidosi
year
die
fundament
patholog
abnorm
diseas
format
noncas
epithelioid
granuloma
usual
confin
poorli
solubl
foreign
materi
simpli
remov
singl
phagocyt
cell
key
featur
sarcoidosi
activ
cell
differenti
type
helper
cell
secret
interleukin
interferon
augment
macrophag
tumour
necrosi
amplifi
local
cellular
immun
granulomat
inflamm
interfer
local
tissu
homeostasi
lead
organ
impair
sinc
sarcoidosi
primarili
involv
lung
eye
skin
attent
focus
airborn
environment
antigen
might
trigger
presum
hypersensit
respons
cellmedi
cellular
immun
similar
granulomat
respons
seen
varieti
infecti
agent
includ
mycobacteria
parasit
schistosoma
fungi
coccidiomycosi
earli
studi
report
associ
noninfect
agent
includ
beryllium
zirconium
aluminium
woodburn
stove
tree
pollen
clay
soil
talc
insecticid
inorgan
particl
moldi
environ
none
theoret
caus
also
severalfold
increas
incid
sarcoidosi
occur
sibl
parent
well
consist
strong
associ
specif
gene
product
class
class
ii
human
leukocyt
antigen
may
add
famili
connect
although
infecti
agent
cultur
directli
sarcoidosi
tissu
clinic
immunolog
characterist
disord
provid
strongest
support
microbi
aetiolog
least
explor
possibl
infecti
caus
patient
seen
moffitt
cancer
center
correl
clinic
present
longterm
followup
patient
sarcoidosi
presenc
bacteri
dna
archiv
surgic
resect
mediastin
lymph
node
result
sarcoidosi
node
compar
control
lymph
node
resect
time
lung
surgeri
nodeneg
stage
nonsmal
cell
lung
cancer
patient
tissu
clinic
data
studi
obtain
approv
moffitt
cancer
center
scientif
review
committe
protocol
mcc
univers
south
florida
irb
protocol
search
moffitt
cancer
center
surgic
patholog
databas
januari
april
retrospect
identifi
randomli
chosen
patient
diagnos
sarcoidosi
base
typic
radiograph
clinic
present
histolog
find
noncas
epithelioid
granulomata
lymph
node
obtain
steril
mediastinoscopi
avoid
possibl
microorgan
contamin
endoscop
biopsi
special
stain
microorgan
neg
specimen
inclus
group
follow
criteria
use
make
diagnosi
sarcoidosi
chest
radiograph
chest
ct
find
symmetr
mediastin
hilar
adenopathi
without
reticulonodular
infiltr
lung
field
see
figur
positron
emiss
tomographi
pet
scan
demonstr
glucos
avid
enlarg
lymph
node
see
figur
asymptomat
present
typic
symptom
dyspnoea
cough
chest
tightnesspain
night
sweat
fever
fatigu
malais
skin
rash
weight
loss
lymph
node
show
histolog
featur
confluent
noncas
granulomata
known
microorgan
caus
granulomata
exclud
histori
cultur
histopatholog
specimen
review
one
author
ps
reconfirm
diagnosi
made
origin
department
pathologist
moffitt
insur
steril
collect
control
specimen
taken
lymph
node
remov
open
thoracotomi
one
author
lar
match
case
randomli
chosen
patient
stage
ia
nonsmal
lung
cancer
lymph
node
select
patient
small
peripher
tumour
obstruct
atelectasi
evid
activ
infect
one
author
ps
review
control
lymph
node
histolog
verifi
whether
metastas
acut
inflamm
granulomata
clinic
data
patient
demograph
initi
present
symptom
object
find
extract
electron
medic
record
patient
sarcoidosi
one
author
lar
patient
stage
use
modifi
scad
radiograph
stage
system
stage
normal
chest
xray
stage
hilar
mediastin
adenopathi
alon
stage
adenopathi
pulmonari
infiltr
stage
pulmonari
infiltr
alon
stage
pulmonari
longterm
followup
clinic
statu
subsequ
treatment
regimen
patient
sarcoidosi
obtain
electron
medic
record
telephon
call
place
patient
immedi
famili
deidentifi
formalinfix
paraffinembed
block
lymph
node
sarcoidosi
control
patient
sent
depart
laboratori
medicin
microbiolog
univers
washington
seattl
washington
usa
investig
blind
ident
specimen
dna
extract
paraffinembed
block
perform
paraffin
remov
incub
xylen
use
roch
highpur
pcr
templat
purif
kit
roch
diagnost
gmbh
mannheim
germani
sever
neg
patient
sampl
unrel
present
studi
includ
batch
rule
contamin
inhibit
rule
check
abil
exogen
ad
target
dna
amplifi
pcr
mix
contain
dna
extract
clinic
specimen
mycobacterium
tuberculosi
bartonella
hensela
detect
multipl
time
past
use
pcr
assay
primer
use
broad
rang
bacteria
rpob
broad
rang
mycobacteria
spp
pcr
detect
nonmycobacterium
spp
dna
propionibacterium
acn
mycobacterium
spp
dna
detect
andor
rpob
primer
primer
use
amplif
also
use
amplicon
sequenc
pcr
amplicon
directli
sequenc
clone
perform
mix
infect
detect
set
specimen
align
blastn
use
identif
base
exact
match
case
sequenc
could
link
microb
detect
p
acn
detect
primer
mycobacterium
avium
detect
primer
avium
detect
identifi
sequenc
analysi
gene
fragment
amplifi
previous
gene
amplifi
use
primer
rna
polymeras
subunit
gene
rpob
amplifi
use
mf
mr
amplifi
product
sequenc
use
big
dye
sequenc
kit
appli
biosystem
foster
citi
california
usa
per
vendor
recommend
protocol
sequenc
two
strand
assembl
doublestrand
contig
use
sequench
softwar
gene
code
ann
arbor
michigan
usa
final
sequenc
use
search
nation
center
biotechnolog
inform
nation
institut
health
databas
use
basic
local
align
search
tool
blast
identifi
amplifi
dna
primari
variabl
compar
sarcoidosi
control
patient
number
patient
group
bacteri
dna
found
lymph
node
two
proport
test
compar
independ
proport
small
sampl
size
use
compar
result
two
addit
or
ci
numer
data
express
patient
age
mean
year
median
year
rang
year
male
femal
ratio
ethnic
includ
caucasian
africanamerican
hispan
patient
overweight
mean
bodi
mass
index
median
rang
time
initi
present
patient
symptomat
usual
multipl
symptom
patient
durat
symptom
diagnosi
mean
month
median
month
rang
month
common
symptom
night
sweat
dyspnoea
chest
pain
chest
tight
fever
fatigu
skin
rash
stomach
ulcer
symptom
present
least
one
patient
includ
dyspepsia
dysphagia
diarrhoea
constip
kidney
stone
joint
muscl
pain
orthopnoea
nose
mouth
skin
lesion
intermitt
bronchospasm
malais
weight
loss
comorbid
includ
asthma
coronari
arteri
diseas
diabet
mellitu
hypertens
one
gout
hypothyroid
eczema
fibromyalgia
crohn
diseas
malign
extrem
common
half
current
prior
tumour
find
note
previous
malign
prior
time
present
breast
melanoma
uterin
sarcoma
tonsil
ovari
adren
colon
hodgkin
lymphoma
chest
ct
perform
patient
symmetr
mediastin
hilar
adenopathi
four
patient
obviou
abdomin
adenopathi
lung
nodul
present
patient
radiograph
stage
ii
sarcoidosi
patient
stage
diseas
stage
ii
patient
symptomat
petct
scan
perform
patient
sarcoidosi
patient
demonstr
glucos
avid
enlarg
mediastin
hilar
node
see
figur
typic
exampl
glucos
avid
seen
abnorm
abdomin
node
four
patient
radiograph
adenopathi
diaphragm
twelv
patient
lymph
node
tissu
sent
time
mediastinoscopi
aerob
fungal
mycobacteri
cultur
cultur
show
growth
week
incub
eleven
lymph
node
patient
sarcoidosi
bacteri
dna
present
pcr
control
patient
found
bacteri
dna
lymph
node
microorgan
present
group
shown
tabl
significantli
patient
sarcoidosi
lymph
node
posit
microorgan
dna
control
lymph
node
versu
p
valu
ci
patient
sarcoidosi
detect
bacteri
dna
lymph
node
symptomat
present
addit
bacteri
dnaposit
patient
sarcoidosi
symptomat
present
radiograph
stage
ii
diseas
longterm
followup
complet
patient
sarcoidosi
mean
followup
month
median
month
rang
month
five
patient
deceas
three
cancer
one
chronic
obstruct
pulmonari
diseas
one
unknown
caus
five
patient
lost
direct
followup
still
live
base
inform
obtain
social
secur
death
patient
sarcoidosi
bacteri
dna
found
lymph
node
seri
longterm
followup
avail
symptomat
mean
followup
month
median
month
rang
month
one
addit
bacteri
dnaposit
patient
lost
followup
expect
molecular
test
use
pcr
demonstr
onethird
patient
sarcoidosi
evid
bacteri
dna
node
indic
either
past
current
involv
microorgan
percentag
bacteri
dnaposit
specimen
fall
rang
found
numer
prior
publish
studi
past
two
decad
use
variou
methodolog
rang
posit
tabl
furthermor
atyp
mycobacteria
p
acn
repres
almost
dna
identifi
also
consist
find
multipl
prior
studi
tabl
addit
identifi
one
skin
mucou
membran
organ
corynebacterium
propinquum
one
aerob
gramneg
bacillu
duganella
zoogloeoid
usual
found
aqueou
environ
interestingli
latter
patient
zoogloeoid
asbesto
technician
origin
tropic
haiti
disclaim
find
dna
microorgan
lymph
node
tell
us
whether
viabl
organ
present
whether
caus
granulomat
reaction
similar
prior
publish
studi
summaris
tabl
significantli
less
control
lymph
node
resect
time
lung
cancer
surgeri
show
evid
bacteri
dna
avium
p
acn
differ
strongli
suggest
demonstr
bacteri
dna
sarcoidosi
lymph
node
real
find
studi
prior
publish
studi
process
contamin
therefor
point
microorgan
potenti
contributor
genesi
diseas
addit
p
acn
dna
found
control
lymph
node
studi
stark
contrast
ishig
et
japan
report
microorgan
ubiquit
pulmonari
lymph
node
commens
found
nonsarcoid
patient
studi
high
posit
result
studi
like
due
either
geographicalethnicraci
differ
potenti
contamin
process
perhap
intrigu
find
came
correl
pcr
find
clinic
inform
patient
lymph
node
contain
bacteri
dna
present
also
highli
symptomat
poorerprognosi
radiograph
stage
ii
find
moreov
median
year
followup
bacteri
dnaposit
patient
still
highli
symptomat
strike
correl
strongli
suggest
demonstr
bacteri
dna
pcr
lymph
node
initi
present
advers
prognost
factor
make
unlik
patient
spontan
remiss
inde
infect
one
microorgan
trigger
exuber
granulomat
immun
respons
patient
usual
spontan
like
clear
offend
organ
immun
reaction
subsid
postul
patient
persist
symptomat
diseas
like
continu
harbour
microorgan
perpetu
vigor
destruct
immun
respons
well
permit
microorgan
travel
elsewher
organ
creat
distant
granulomat
inflamm
mani
pathogen
microorgan
mycobacterium
lepra
leprosi
coronavirus
sever
acut
respiratori
syndrom
grown
directli
cultur
slow
grow
difficult
cultur
tropheryma
whippelii
whippl
diseas
instanc
detect
identif
reli
molecular
mechan
pcr
use
studi
nevertheless
molecular
approach
distinct
limit
includ
possibl
falseposit
result
secondari
contamin
pcr
reagent
paraffin
embed
process
postembed
handl
process
paraffin
block
howev
studi
control
lymph
node
process
ident
manner
bacteri
dna
detect
significantli
less
sarcoidosi
node
suggest
contamin
unlik
account
find
anoth
obviou
limit
interpret
result
prior
molecular
studi
relat
colonis
versu
causat
find
microbi
dna
node
prove
organ
activ
involv
pathogenesi
diseas
microorgan
may
commens
theoret
might
even
attract
area
granulomat
inflamm
nevertheless
mark
differ
percentag
microbi
dnaposit
node
sarcoidosi
versu
control
patient
certainli
suggest
diseas
causat
microorgan
addit
number
lymph
node
posit
bacteri
dna
may
significantli
underestim
tendenc
formalinfix
paraffin
embed
process
breakdown
prokaryot
dna
time
investig
found
degrad
prokaryot
bacteri
dna
especi
mycobacteria
age
paraffinembed
note
three
sarcoidosi
lymph
node
posit
mycobacteria
studi
less
year
old
evalu
pcr
use
fresh
lymph
node
tissu
like
drake
et
found
pcr
posit
mycobacteria
spp
may
much
higher
rate
posit
bacteri
dna
result
particularli
mycobacteria
studi
sarcoidosi
granulomat
diseas
primarili
involv
lung
lymph
node
organ
appear
result
exuber
cell
macrophag
immunolog
respons
continu
present
poorli
degrad
antigen
numer
noninfect
agent
implic
base
epidemiolog
studi
none
stood
focu
past
two
decad
infect
agent
might
trigger
sarcoidosi
strongest
suspect
found
mycobacteria
famili
common
commens
p
acn
like
classic
tuberculosi
peopl
infect
tuberculosi
remain
remiss
without
sarcoidosi
also
spontan
remiss
rate
without
one
may
specul
similar
tuberculosi
immun
system
initi
respons
trigger
microorgan
success
erad
agent
immun
respons
subsid
persist
progress
sarcoidosi
organ
remain
viabl
perpetu
destruct
immun
respons
symptomat
sarcoidosi
usual
treat
variou
antiinflammatori
immunosuppress
agent
corticosteroid
methotrex
tnfinhibitor
biolog
similar
immunolog
abnorm
treatment
anoth
debilit
granulomat
diseas
crohn
diseas
granulomat
ileiti
crohn
suspect
mani
investig
result
chronic
infect
oblig
intracellular
microorgan
avium
subspeci
paratuberculosi
map
known
caus
granulomat
ileiti
cattl
rumin
call
john
although
classic
treatment
crohn
diseas
immunosuppress
agent
like
sarcoidosi
mani
recent
studi
suggest
much
effect
treatment
less
side
effect
may
tripl
antibiot
regimen
gear
toward
put
trigger
agent
fact
mani
field
suspect
intracellular
organ
map
resid
macrophag
impair
normal
autophagi
would
usual
erad
agent
enhanc
autophagi
current
human
trial
may
prove
effect
along
antibiot
crohn
antibacterialantimycobacteri
regimen
use
crohn
diseas
alter
natur
histori
sarcoidosi
chronic
symptomat
patient
sixti
year
ago
number
small
trial
use
classic
antitubercul
drug
isoniazid
streptomycin
cortison
publish
discourag
howev
atyp
mycobacteria
rather
tuberculosi
like
one
aetiolog
agent
sarcoidosi
almost
resist
standard
antituberculosi
agent
organ
p
acn
perhap
cellwal
defici
lform
bacteria
trigger
perpetu
sarcoidosi
individu
standard
antitubercul
drug
would
also
ineffect
tetracyclin
deriv
minocyclin
doxycyclin
well
antimalari
drug
chloroquin
shown
quit
effect
treat
cutan
minocyclin
produc
complet
respons
twothird
case
although
debat
whether
antimicrobi
effect
immunomodul
attent
recent
turn
randomis
sarcoidosi
treatment
trial
variou
antimicrobi
agent
drake
et
publish
posit
result
first
randomis
trial
antimicrobi
regimen
direct
atyp
mycobacteria
usa
use
oral
concomit
levofloxacin
ethambutol
azithromycin
rifampin
clear
regimen
treat
patient
cutan
sarcoidosi
quit
signific
reduct
cutan
lesion
size
gupta
et
comprehens
review
sarcoidosi
similar
tuberculosi
present
convinc
case
antitubercul
treatment
sarcoidosi
gupta
also
princip
investig
ongo
clinic
trial
india
use
standard
antitubercul
therapi
rifampicin
isoniazid
along
prednisolon
compar
prednisolon
alon
treatment
sarcoidosi
pilot
random
control
trial
clinicaltrialsgov
identifi
result
trial
india
high
burden
tuberculosi
avail
next
year
though
drug
regimen
use
may
effect
countri
low
tuberculosi
burden
inde
sarcoidosi
aris
abnorm
immunolog
respons
microorgan
patient
geograph
locat
may
dictat
microorgan
involv
antimicrobi
regimen
effect
past
three
decad
numer
studi
examin
everi
aspect
sarcoidosi
includ
dysfunct
immun
respons
primari
therapi
immun
suppress
variou
form
treat
symptom
seem
alter
natur
histori
dozen
studi
tabl
repeatedli
demonstr
evid
microorgan
sarcoidosi
tissu
mostli
variou
mycobacteria
p
acn
molecular
studi
like
warrant
perhap
follow
lead
crohn
diseas
proceed
therapeut
clinic
trial
use
regimen
multipl
antibiot
patient
persist
symptomat
advancedstag
sarcoidosi
inde
persist
viabl
microorgan
infect
caus
continu
progress
debilit
symptom
organ
failur
antibiot
might
favour
impact
cours
diseas
